Article Sidebar
Article Details
Issue
Section
Articles
Copyright © 2017 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights reserved
Main Article Content
Clinical significance of sCD86 levels in patients with acute myelogenous leukemia
Abstract
Introduction: CD86 (B72) molecules are surface glycoproteins and members of Ig superfamily that are expressed only on professional APCs and are important in the early interactions between APCs and T cells during the induction of immune response. It is well established that
mCD86 is expressed by AML blasts in a considerable proportion of patients. The release of soluble forms of membrane molecules provides a powerful means by which leukocytes can either inhibit or enhance the biological effects relative of their membrane-bound counterparts, and there is now considerable evidence to support the possibility that the release of a soluble form of CD86 (sCD86) has an immunoregulatory role in vivo. The observation that sCD86 levels are highest in the FAB subtypes
with the highest AML blast levels, together with the observation that high levels of sCD86 are associated with poor prognosis, strongly suggests that sCD86 is derived from the malignant cells in these patients.
The aim: The present study was to assess levels of sCD86 in de novo acute myeloid leukemia patients and to determine any possible correlation with outcome following induction chemotherapy. The study was carried out on 30 patients with de novo acute myeloid leukemia and 20 healthy
controls.
Method: Levels of soluble CD86 (sCD86) in the serum was measured using ELISA technique at presentation and after one cycle of induction chemotherapy.
Conclusion: We found that sCD86 was detected in both patients and controls. Levels of sCD86 were higher than the cut-off value in 36.6% of patients. There was a significant difference between levels of sCD86 before and after treatment. Patients (54.5%) with high sCD86 levels had monocytic morphology. Patients with high levels of sCD86 had a lower rate of complete remission.
mCD86 is expressed by AML blasts in a considerable proportion of patients. The release of soluble forms of membrane molecules provides a powerful means by which leukocytes can either inhibit or enhance the biological effects relative of their membrane-bound counterparts, and there is now considerable evidence to support the possibility that the release of a soluble form of CD86 (sCD86) has an immunoregulatory role in vivo. The observation that sCD86 levels are highest in the FAB subtypes
with the highest AML blast levels, together with the observation that high levels of sCD86 are associated with poor prognosis, strongly suggests that sCD86 is derived from the malignant cells in these patients.
The aim: The present study was to assess levels of sCD86 in de novo acute myeloid leukemia patients and to determine any possible correlation with outcome following induction chemotherapy. The study was carried out on 30 patients with de novo acute myeloid leukemia and 20 healthy
controls.
Method: Levels of soluble CD86 (sCD86) in the serum was measured using ELISA technique at presentation and after one cycle of induction chemotherapy.
Conclusion: We found that sCD86 was detected in both patients and controls. Levels of sCD86 were higher than the cut-off value in 36.6% of patients. There was a significant difference between levels of sCD86 before and after treatment. Patients (54.5%) with high sCD86 levels had monocytic morphology. Patients with high levels of sCD86 had a lower rate of complete remission.
